Heart Center: Research & Publications

Heart Attack

Investigational medication that reduce cardiovascular inflammation following a heart attack.
Contact: Brian Kahn, MD, FACC at 410-663-6986 or Vicki Coombs, PhD, RN, at 410-615-6641
FDA-approved medication designed to prevent blood clot formation following a heart attack.
Contact: Brian Kahn, MD, FACC at 410-663-6986 or Vicki Coombs, PhD, RN, at 410-615-6641
Investigational medication that reduces the formation of plaque in the coronary arteries following a heart attack.
Contact: Brian Kahn, MD, FACC at 410-663-6986 or Vicki Coombs, PhD, RN, at 410-615-6641
Patients with existing cardiovascular disease and Type 2 Diabetes receive an FDA approved diabetes medication as an add-on to their current diabetes regimen. Study drug is designed to reduce hemoglobin A1c and is potentially cardio-protective.
Contact: Brian Kahn, MD, FACC at 410-663-6986 or Vicki Coombs, PhD, RN, at 410-615-6641

Investigational medication for patients with existing cardiovascular disease and high cholesterol. Study medication increases HDL (good cholesterol ) 138% and lowers total cholesterol by 40%.
Contact: Brian Kahn, MD, FACC at 410-663-6986, Frank Morris, MD, FACC at 443-275-5655 or Vicki Coombs, PhD, RN, At 410-615-6641.

Patients with existing cardiovascular disease and Type 2 Diabetes receive an FDA approved diabetes medication as an add-on to their current diabetes regimen. Study drug is designed to reduce hemoglobin A1c and is potentially cardio-protective.
Contact: Brian Kahn, MD, FACC at 410-663-6986 or Vicki Coombs, PhD, RN, at 410-615-6641
Patients with Type 2 Diabetes and high blood pressure receive an investigational medication to reduce hemoglobin A1c and reduce blood pressure.
Contact: Fernando Ferro, MD at 410-663-3200 or Vicki Coombs, PhD, RN at 410-615-6641

Patients with mild to moderate congestive heart failure receive investigational medication as an add-on to their current medication regimen to improve their symptoms.
Contact: Brian Kahn, MD, FACC at 410-663-6986 or Vicki Coombs, PhD, RN, at 410-615-6641

FDA-approved medication to lower blood pressure in adults
Contact: Brian Kahn, MD, FACC at 410-663-6986 or Vicki Coombs, PhD, RN, at 410-615-6641
Investigational medication to lower blood pressures in adults 18-54 years of age
Contact: Frank Morris, MD, FACC at 443-275-5000 or Vicki Coombs, PhD, RN at 410-615-6641

Harvard Clinical Research Institute: A prospective, multi- center, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy (DAPT) in subjects undergoing percutaneous coronary intervention (PCI) with either drug-eluting stent (DES) or bare metal stent (BMS) placement for the treatment of coronary artery lesions. (The DAPT Study), HCRI, 2010-Present.
Contact: Amish C. Sura, M.D., FACC at 410-332-9752

A Prospective, Single Blind, Randomized Controlled Study to Evaluate the Safety And Effectiveness of the Tryton Side Branch Stent™ used in Conjunction with a Drug-Eluting Stent Compared to Side Branch Balloon Angioplasty in Conjunction with a Drug-Eluting Stent in the Treatment of de novo Bifurcation Lesions Involving the Main Branch and Side Branch within the Native Coronary Circulation. (TRYTON Study). 2011-Present.
Contact: Amish C. Sura, M.D., FACC at 410-332-9752

Evaluation of XIENCE Prime or XIENCE V vs Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization (EXCEL Study) 2010-Present.
Contact: Amish C. Sura, M.D., FACC at 410-332-9752

Now Accepting New Patients.
Most Insurances Accepted.

Please call for an appointment.
Phone: 410-332-9752
Tollfree: 1-800-MD-Mercy (1-800-636-3729)